Biodesix (BDSX)

The company operates as a single business segment and earns revenue from two main activities. The first is clinical diagnostic testing, including blood-based lung tests and tests developed for COVID-related use. The second is work performed for biopharmaceutical customers, such as diagnostic research, clinical trial testing, assay development, and support for companion diagnostic programs. These services are typically governed by individual contracts and may be used by drug developers as they evaluate targeted therapies or identify patient groups for clinical studies.

Biodesix sits at the intersection of molecular diagnostics, proteomics, genomics, and precision medicine. Its business depends on test adoption by healthcare providers, reimbursement from payers, and demand from pharmaceutical and biotechnology companies. As a listed diagnostics stock, BDSX gives investors exposure to a specialised healthcare company whose growth is tied to the expanding role of data-driven testing in lung disease care and drug development.